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Targeting Rho GTPase Signaling
Networks in Cancer
Natasha S. Clayton and Anne J. Ridley*
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
As key regulators of cytoskeletal dynamics, Rho GTPases coordinate a wide range
of cellular processes, including cell polarity, cell migration, and cell cycle progression.
The adoption of a pro-migratory phenotype enables cancer cells to invade the stroma
surrounding the primary tumor and move toward and enter blood or lymphatic vessels.
Targeting these early events could reduce the progression to metastatic disease, the
leading cause of cancer-related deaths. Rho GTPases play a key role in the formation
of dynamic actin-rich membrane protrusions and the turnover of cell-cell and cell-
extracellular matrix adhesions required for efficient cancer cell invasion. Here, we
discuss the roles of Rho GTPases in cancer, their validation as therapeutic targets
and the challenges of developing clinically viable Rho GTPase inhibitors. We review
other therapeutic targets in the wider Rho GTPase signaling network and focus on the
four best characterized effector families: p21-activated kinases (PAKs), Rho-associated
protein kinases (ROCKs), atypical protein kinase Cs (aPKCs), and myotonic dystrophy
kinase-related Cdc42-binding kinases (MRCKs).
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INTRODUCTION
Rho GTPases are a family of highly conserved GTPases that are encoded by 20 genes in humans
and regulate a range of cellular functions, including vesicular transport, gene expression, neuronal
development, and cell division. By far the best characterized of Rho GTPase functions is the
organization of the actin cytoskeleton into structures required for cell migration. In cancer, the
adoption of a pro-migratory phenotype enables tumor cells to invade the stroma surrounding the
primary tumor, migrate toward blood vessels and enter the circulation (Figure 1A). Migrating
cells extend membrane protrusions at the leading edge, which are driven forward by localized
actin polymerization (Figure 1B). In general, the formation of lamellipodia is regulated by Rac
and Rho, whilst Cdc42 activity drives the formation of filopodia and maintains the cellular
polarization required for directional migration. Rho regulates actomyosin contractility, which
can lead to the formation of actin stress fibers and focal adhesions on rigid substrata, which
are required to generate the traction forces needed to pull the cell body in the direction of
movement. Migration of cells in 3D often requires the degradation of matrix components by
proteases released from invadopodia, which are actin-rich structures regulated by RhoA, RhoC,
and Cdc42 (Lawson and Ridley, 2018).
Altered expression of several Rho GTPases has been reported in a variety of human tumors
(reviewed in Svensmark and Brakebusch, 2019). Whilst mutations in genes encoding Rho GTPases
are rare in cancer, somatic mutations have been reported in RHOA, RHOB, RAC1, RAC2, and
CDC42 (Hurst et al., 2017; Aspenström, 2018). Here, we comment on the recent advances in
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targeting Rho GTPase activation and focus on inhibition
of Rho GTPase effectors as a viable therapeutic strategy in
cancer treatment.
TARGETING RHO GTPASE ACTIVATION
The binding of GTP to the nucleotide binding pocket of
membrane anchored Rho GTPases leads to a conformational
change that stimulates their interaction with various downstream
effectors, including protein kinases and scaffold/adaptor-like
proteins. The activity of most Rho GTPases is terminated by the
hydrolysis of bound GTP to GDP, and the dissociation of GDP is
required before another GTP molecule can bind. For the classical
Rho GTPases, this cycling between GTP- and GDP-bound states
is tightly regulated by guanine nucleotide exchange factors
(GEFs) and GTPase-activating proteins (GAPs) (Figure 2). Rho
GTPases can also be regulated by guanine nucleotide dissociation
inhibitor (GDI) binding, which sequesters Rho GTPases in the
cytoplasm (Golding et al., 2019).
Significant effort has been made to develop compounds
that modulate multiple stages of the GDP/GTP cycle (Jansen
et al., 2018; Maldonado and Dharmawardhane, 2018). These
include compounds that inhibit GEF-GTPase binding, which
have produced promising results in preclinical cancer models.
For example, EHop-016 blocks the interaction of Rac1 with Vav2
(Montalvo-Ortiz et al., 2012), and has been shown to enhance the
anti-tumor effect of cisplatin in xenograft models of esophageal
squamous cell carcinoma (Zeng et al., 2019). ZCL278 blocks the
interaction of Cdc42 with intersectin (Friesland et al., 2013) and
can inhibit the growth of lung cancer xenografts (Aguilar et al.,
2019). It is important to note that the activity of atypical Rho
GTPases is unlikely to be regulated by GEF/GAP interactions
(Aspenstrom et al., 2007; Hodge and Ridley, 2017), and therefore
alternative strategies will be required to target these family
members effectively.
In contrast to the prevailing view that the GDP-bound forms
of Rho GTPases are inactive, recent data have identified a role
for Rho-GDP in oncogenic signaling. The RhoA driver mutation
G17V, which disrupts GTP binding, is frequently identified in
T-cell lymphoma (Yoo et al., 2014) and studies in Dictyostelium
cells demonstrate that phosphorylation of RhoA-GDP at S192
leads to increased mTORC2 activity and phosphorylation of
AKT (Senoo et al., 2019). These findings suggest that, in certain
cancers, targeting GTP-bound Rho GTPases may offer little
therapeutic benefit.
Membrane localization of Rho GTPases following post-
translational C-terminal lipid modifications, including
prenylation and palmitoylation, is crucial for their
function (Mitin et al., 2012). The therapeutic potential of
prenylation inhibitors is currently being investigated. The
geranylgeranyltransferase type I inhibitor GGTI-2418 (PTX-
100) has shown anti-tumor effects in breast cancer xenograft
models (Aspenstrom et al., 2007) and was well tolerated in
an initial phase I clinical trial (Karasic et al., 2019), although
further phase I trials are required to optimize dosing and
assess responses in patients with advanced malignancies
(NCT03900442). Rho GTPase membrane localization can also be
inhibited by treatment with statins, which suppress cholesterol
biosynthesis, reducing the abundance of farnesyl pyrophosphate
and geranylgeranyl pyrophosphate (Denoyelle et al., 2001).
Statins are widely prescribed for treatment of cardiovascular
disease (Tobert, 2003) and have been reported to reduce cancer
recurrence and mortality in several cancer types (Beckwitt et al.,
2018). However, this likely reflects the modulation of multiple
pathways by statins, including inhibition of Rho GTPases.
A more promising approach to targeting Rho GTPase
signaling is through the direct inhibition of Rho GTPase effectors.
Here, we discuss the roles of PAKs, ROCKs, MRCKs, and aPKCs
in Rho GTPase signaling and review recent advances in targeting
these proteins in cancer.
P21-ASSOCIATED KINASES (PAKS)
The best characterized Rho GTPase effectors are the highly
conserved p21-activated kinases (PAKs), which are found in
almost all eukaryotes except plants (Hofmann et al., 2004). In
humans, the PAKs comprise a family of six serine/threonine
kinases which can be divided into two subgroups based on
sequence homology and structural similarity. All PAKs possess an
N-terminal Cdc42- and Rac-Interactive Binding (CRIB) domain,
which mediates their interaction with GTP-bound Rho GTPases,
and a conserved kinase domain at the C-terminus (Figure 3).
Group I PAKs (PAK1-3) possess an autoinhibitory domain
which interacts with the kinase domain in a cis-autoinhibitory
interaction. GTPase binding disrupts this autoinhibition and
leads to the dimerization and trans-autophosphorylation of two
PAK monomers, resulting in their full activation (Sorrell et al.,
2019). In contrast, group II PAKs (PAK4-6) show constitutive
activation loop autophosphorylation, which is not affected by the
binding of Rho GTPases. Group II PAKs are instead activated
by the dissociation of a proline-rich psudosubstrate region from
the kinase domain, which may be triggered by the binding of
an SH3-domain containing protein (Ha et al., 2012). According
to this model, Rho GTPases may promote the activation of
group II PAKs by facilitating these protein-protein interactions.
PAKs were initially identified as hits in a screen for Cdc42 and
Rac1 binding partners (Manser et al., 1994) and have since been
shown to interact with a number of other Rho GTPases. PAK
signaling downstream of Rho GTPase activity contributes to
multiple cellular responses including cell migration, cell survival
and sensitivity to certain chemotherapeutic agents (Figure 4;
Rane and Minden, 2019).
PAKs are involved in membrane protrusion and focal
adhesion turnover by promoting the phosphorylation of proteins
involved in actin dynamics (Figure 4). Following activation
by Cdc42/Rac1, PAK1 phosphorylates LIM Kinase-1 (LIMK1),
which in turn phosphorylates and inactivates cofilin, suppressing
the disassembly of actin filaments at the leading edge. Interaction
of Rac1 with the WAVE regulatory complex leads to activation
of the actin nucleation complex Arp2/3, which when combined
with localized inactivation of cofilin, leads to formation of the
branched actin network characteristic of lamellipodia (Jansen
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FIGURE 1 | (A) Stages of cancer metastasis. A subset of cancer cells in the primary tumor acquire an invasive phenotype and spread into the surrounding stroma,
either collectively or as single cells. Some invading cells migrate toward the tumor neovasculature and enter the blood stream by migrating through vascular
endothelial cell junctions in a process known as intravasation. These cancer cells can be transported by the circulation to distal tissues, where they enter narrower
vessels that permit their attachment to vascular endothelial cells. Following attachment, cancer cells commonly extravasate as single cells by migrating through
endothelial cell junctions and then invade into the stroma of the secondary organ. These cells may form a metastatic niche if supported by survival and growth
signals in the new micro-environment. Further cell proliferation will give rise to micro- and macro-metastases and a secondary tumor is established by the formation
of a new blood supply through neo-angiogenesis. (B) Modes of cell migration. Elongated cell migration involves the extension of actin-rich protrusions at the front of
the cell and the localized release of matrix metalloproteinases (MMPs), which degrade extracellular matrix (ECM) proteins and create space into which the cell can
move. The formation of new adhesions at the front of the cell and contraction of the cell body pull the cell in the direction of movement, whilst loss of ECM adhesions
at the rear allows the cell to migrate forward. During collective cell migration, neighboring cells within a tissue remain physically linked by adherens junctions. Cells at
the invasive front extend actin-rich protrusions facing the direction of movement, which form new adhesions with the ECM and enable the generation of traction
forces that pull neighboring cells forward. During rounded cell migration, high actomyosin contractility produces hydrostatic pressure, which leads to the formation of
membrane blebs devoid of filamentous actin at the front of the migrating cell. Highly dynamic membrane blebs fill pre-existing spaces in the matrix and form only
weak attachments to the ECM.
et al., 2018). In breast cancer cell lines, PAK4 has been shown
form a complex with RhoU, providing a scaffold leading to
increased phosphorylation of paxillin at S272, a crucial step in
focal adhesion turnover (Nayal et al., 2006; Dart et al., 2015).
PAKs also contribute to cell migration and invasion by
influencing the spatiotemporal activation of Rho GTPases. PAK4
is known to directly bind and inhibit PDZ-RhoGEF (Barac et al.,
2004), leading to an indirect inhibition of RhoA. In melanoma
cell lines, depletion of PAK4 was associated with an increase
in RhoA activity and a decrease in the percentage of cells with
mature degradative invadopodia. Expression of PDZ-RhoGEF
dominant negative mutants rescued invadopodia in PAK4-
depleted melanoma cells, which suggests that a PAK4-mediated
reduction in RhoA activity is required for invadopodium
maturation. In the same cell lines, depletion of PAK1 was
associated with a decrease in RhoA activity and fewer nascent
invadopodial actin puncta, suggesting that PAK1 acts upstream
of PAK4 to drive the early stages of invadopodium formation
(Nicholas et al., 2016). This suggests that, in addition to the
tight spatiotemporal control of RhoC activity (Bravo-Cordero
et al., 2011), co-ordinated activation of RhoA at different
stages of the invadopodium lifecycle is required for efficient
cancer cell invasion.
Group I PAKs can bind directly to the GEFs α-PIX and
β-PIX and influence their activity and/or localization (Manser
et al., 1998). PAK1 binding has been shown to stimulate the GEF
activity of α-PIX, resulting in an increase in GTP-bound Cdc42
(Daniels et al., 1999). Other work has shown that PAK1 and
Rac1 compete for binding to β-PIX and that the PAK1-β-PIX
interaction is negatively regulated by PAK1 autophosphorylation.
This may provide a mechanism through which other Rho
GTPases, such as Cdc42, influence the spatio-temporal activation
of Rac1 (ten Klooster et al., 2006). However, PAK1 activation at
the leading edge of fibroblasts has been shown to recruit β-PIX
Frontiers in Cell and Developmental Biology | www.frontiersin.org 3 April 2020 | Volume 8 | Article 222
fcell-08-00222 April 2, 2020 Time: 8:23 # 4
Clayton and Ridley Rho GTPase Signaling in Cancer
FIGURE 2 | Schematic representation of the classical Rho GTPase regulatory
cycle. GDP-bound Rho GTPases are prenylated at a C-terminal CAAX
sequence by farnesyltransferase (FTase) and/or geranylgeranyltransferase
type I (GGTase-I), which mediates their association with biological
membranes. Rho guanine nucleotide exchange factors (RhoGEFs) promote
the dissociation of GDP and uptake of GTP, which permits the interaction of
Rho GTPases with effector proteins. GTPase-effector interactions are
terminated by the hydrolysis of bound GTP to GDP, which is accelerated by
Rho GTPase-activating proteins (RhoGAPs). Both GDP- and GTP-bound Rho
GTPases can be negatively regulated by Rho guanine nucleotide dissociation
inhibitors (RhoGDIs), which bind to and sequester the prenyl group, resulting
in relocalization of the Rho GTPase to the cytoplasm. RhoGDI-Rho GTPase
binding can be regulated by phosphorylation of RhoGDIs by kinases Src, PAK,
and PKC.
and promote Rac1 activation (Cau and Hall, 2005). Thus, the
interplay between PAK1, β-PIX, and Rac1 is likely to be complex
and context specific (Jansen et al., 2018).
PAK1 activation can contribute to chemoresistance in
melanoma through the inhibition of pro-apoptotic signaling
pathways. For example, RhoJ is overexpressed in metastatic
melanoma (Ho et al., 2012) and treatment of melanoma cell lines
with cisplatin was found to promote PAK1 autophosphorylation
in a RhoJ-dependent manner (Figure 4). PAK1 activation
led to an uncoupling of the kinase ATR from its effectors
Chk1 and ATF2, which resulted in an impaired DNA damage
response and reduced apoptosis. The observation that PAK1
depletion sensitized melanoma cell lines to cisplatin suggests
that combination treatments of PAK1 inhibitors and DNA-
damaging agents may improve chemoresponsiveness in certain
human tumors (Ho et al., 2012). In addition, BRAF mutant
melanoma cell lines, PAK1 has been shown to phosphorylate the
pro-apoptotic protein Bad (Figure 4), preventing its association
with Bcl-2 and the subsequent release of cytochrome C from
mitochondria (Schurmann et al., 2000; Ruiz et al., 2017).
Treatment with the PAK inhibitor FRAX597 led to a decrease in
Bad phosphorylation and induced more apoptosis within 24 h in
BRAF mutant RhoJ positive melanoma cell lines than the BRAF
inhibitors Vemurafenib and Trametinb (Ruiz et al., 2017).
Several ATP-competitive PAK inhibitors have been developed,
although specificity has proven challenging, due to the structural
similarity of PAK catalytic domains, as well as the relative
flexibility and “open” conformation of the ATP-binding cleft
(Semenova and Chernoff, 2017). FRAX597 is an orally available
group I PAK inhibitor which has been shown to inhibit cancer
cell growth in vitro (Chow et al., 2012; Semenova et al.,
2017; Tan et al., 2017; Araiza-Olivera et al., 2018) and to
sensitize orthotopic tumors to gemcitabene in a murine model of
pancreatic cancer (Yeo et al., 2016). The closely related inhibitor
FRAX486 showed anti-proliferative effects in a mouse model of
childhood acute lymphoblastic leukemia (Siekmann et al., 2018)
and the analog FRAX1036 was recently found to inhibit tumor
growth in murine models of breast (Korobeynikov et al., 2019)
and thyroid (Knippler et al., 2019) cancer. However, FRAX1036
has been found to adversely inhibit hERG potassium channels,
suggesting that FRAX1036 and its analogs may not suitable
for clinical use (Ndubaku et al., 2015). Glaucarubinone, first
developed as an antimalarial, was found to inhibit the activation
of both PAK1 and PAK4, which may prove advantageous in
treating cancers where the co-ordinated activity of these isoforms
contributes to disease progression (Yeo et al., 2014; Nicholas
et al., 2016). Glaucarubinone reduced the growth of pancreatic
cancer xenografts, and glaucarubinone and gemcitabine were
found to have a synergistic effect on the inhibition of PAK1/4
activation and tumor growth (Yeo et al., 2014). Although
originally developed as a PAK4 inhibitor, the Pfizer compound
PF-3758309 inhibits all PAK family kinases and is the only
ATP-competitive PAK inhibitor to have reached clinical trials
(Semenova and Chernoff, 2017). Following a phase I trial in
patients with advanced solid tumors, PF-3758309 was withdrawn
from clinical investigation due to poor bioavailability, adverse
effects and lack of tumor response (Mileshkin et al., 2011).
KPT-9274 is an allosteric PAK4 inhibitor which binds to and
destabilizes PAK4 (Rane et al., 2017). KPT-9274 and its analogs
may therefore prove superior to kinase inhibitors in treating
certain cancers as they could provide dual blockade of PAK4
kinase-dependent and independent functions. KPT-9274 has
been shown to inhibit tumor growth of a number of pre-clinical
cancer models (Rane and Minden, 2019) and is currently in phase
I clinical trials for non-Hodgkin lymphoma and advanced solid
malignancies (NCT02702492).
RHO-ASSOCIATED PROTEIN KINASES
(ROCKS)
The Rho GTPase effectors ROCK1 and ROCK2 are AGC-
family serine/threonine kinases that are involved in a diverse
range of cellular processes, including cell motility, cell survival
and proliferation, gene transcription, differentiation, and
angiogenesis (Wei et al., 2016). Here, we focus on the
role of ROCK in promoting actin polymerization and
actomyosin contractility.
Both ROCKs have an N-terminal kinase domain, a coiled-
coil region containing a Rho-binding domain (RBD) and
a C-terminal pleckstrin homology (PH) domain (Figure 3;
Morgan-Fisher et al., 2013). ROCKs exist as constitutive parallel
homodimers (Truebestein et al., 2015) and interaction with
membrane lipids (Yoneda et al., 2005), cleavage by granzyme
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FIGURE 3 | Domain organization of PAKs, ROCKs, MRCKs, and aPKCs. C, Cdc42- and Rac-Interactive Binding (CRIB) domain; AI, autoinhibitory domain; KD,
kinase domain; AIL, autoinhibitory-like domain; RBD, Rho-binding domain; CC, coiled-coil region; PH, pleckstrin homology domain; CRD, cysteine-rich domain; C1,
C1 domain; CH, citron homology domain; PB1, Phox Bem1 domain; PS, pseudosubstrate motif. Proline-rich regions are indicated by pink bars.
FIGURE 4 | Cancer-associated PAK signaling pathways activated downstream of Rho GTPases. PAK1 phosphorylates LIM Kinase-1 (LIMK-1), which stabilizes actin
filaments through inhibition of cofilin. PAK1 also binds to and stimulates the GEF α-PIX, leading to an increase in Cdc42 activation. PAK1 activates PLK1, which leads
to phosphorylation and degradation of claspin. In the absence of claspin, ATR is uncoupled from its effectors, resulting in an impaired DNA damage response. PAK1
also phosphorylates the pro-apoptotic protein Bad, which prevents its association with Bcl-2 and inhibits apoptosis. PAK4 binding protects RhoU from proteasomal
degradation and promotes focal adhesion turnover by providing a scaffold that promotes the phosphorylation of paxillin. PAK4 also inhibits PDZ-RhoGEF, which
suppresses the activation of RhoA and promotes invadopodia maturation.
B or caspases (Sebbagh et al., 2001; Sebbagh et al., 2005) and
binding of RhoA, RhoB, and RhoC (Amano et al., 2000) have
been shown to stimulate ROCK signaling. ROCK1 and ROCK2
share 92% sequence homology within their kinase domains
(Nakagawa et al., 1996) and have many common substrates
(Yoneda et al., 2005), yet are not functionally redundant
(Jerrell et al., 2017).
During cell migration, ROCK promotes the extension of actin-
rich membrane protrusions through the activation of LIMK1/2
and inhibition of cofilin (Ohashi et al., 2000) and also stimulates
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FIGURE 5 | Role of Cdc42-MRCK signaling and RhoA-ROCK signaling in regulation of the actin cytoskeleton. RhoA directly binds and activates the formin mDia,
which nucleates the formation of unbranched actin filaments. ROCK activation downstream of RhoA leads to phosphorylation of LIMK-1 and LIMK-2, which
phosphorylate and inactivate cofilin, leading to a reduction in actin depolymerization. ROCK activation leads to an increase in actomyosin contractility via
phosphorylation of myosin light chain (MLC) and inhibition of myosin light chain phosphatase (MLCP). ROCK also phosphorylates ERM proteins (ezrin, radixin, and
moesin) and NHE1 (Na+/H+ -Exchanger 1) to enhance coupling of the actin cytoskeleton to integral membrane proteins. Like ROCK, MRCK activation leads to
decreased actin depolymerization via phosphorylation LIMK-1 and LIMK-2 and increased actomyosin contractility via MLC phosphorylation. Phosphorylation of
moesin by MRCKα may enhance coupling of the actin cytoskeleton to integral membrane proteins.
cell body contraction through the generation of actomyosin
contractility (Figure 5). Following activation by RhoA and RhoC,
ROCK directly phosphorylates the myosin light chain (MLC) of
non-muscle myosin II and inhibits MLC phosphatase through
phosphorylation of the myosin binding subunit (Julian and
Olson, 2014). Phosphorylation of MLC on Ser19 and Thr18
influences the ATPase activity of the myosin heavy chain (MHC)
head groups, which move along actin filaments to produce
contractile force (Mizutani et al., 2006). In a 3D environment,
single cells have been shown to utilize two distinct modes of
motility that are driven by different Rho signaling pathways
(Figure 1B). Rac1 activity drives elongated cell motility, which
is characterized by cell polarization, the extension of F-actin-rich
protrusions and degradation of the ECM. In contrast, RhoA/C
signaling through ROCK promotes a rounded bleb-based mode
of motility driven by high levels of actomyosin contractility,
which enables the cell to squeeze into pre-existing spaces and
deform the ECM without the need for significant pericellular
proteolysis (Wyckoff et al., 2006). To adopt a rounded mode of
migration, Rho-ROCK signaling is often coupled to inhibition
of Rac1 signaling, which can be achieved by stimulation of
the Rac GAP ARHGAP22 downstream of ROCK activation.
During elongated cell motility, active Rac1 suppresses the
high levels of actomyosin contractility required for rounded
motility via its effector WAVE2, which negatively regulates
MLC phosphorylation (Sanz-Moreno et al., 2008). Cancer cells
have been shown to convert between elongated and rounded
modes of motility, suggesting that inhibition of both modes
will be required to effectively prevent metastasis, for example
via dual inhibition of secreted proteases and ROCK activity
(Yamada and Sixt, 2019).
Deregulation of Rho-ROCK signaling has been identified
in a number of human cancers and correlated with disease
progression (Rodriguez-Hernandez et al., 2016). The ROCK1
gene is amplified in a number of lung and gastric cancers as
well as in head-and-neck squamous cell carcinoma (Svensmark
and Brakebusch, 2019), whilst ROCK2 amplification has been
associated with peripheral nerve sheath tumors (Upadhyaya et al.,
2012). Three somatic mutations were identified in ROCK1 that
result in activating C-terminal truncations (Lochhead et al., 2010)
and polymorphisms in both ROCK1 and ROCK2 have been
associated with colorectal cancer development (Sari et al., 2013).
Although significant effort has been made to develop
ROCK inhibitors for cancer intervention, the vast majority of
compounds have not progressed to clinical trials. The ATP-
competitive ROCK inhibitors Y-27632 and fasudil have been
used extensively as tool compounds and have been shown to
inhibit cancer cell migration in various in vitro cancer models
(Wei et al., 2016). Although fasudil is clinically approved
for the acute treatment of cerebral vasospasm in Japan and
China, its pharmacokinetic profile makes it unsuitable for use
in chemotherapy (Rath et al., 2018). More recently developed
pan-ROCK inhibitors, such as OXA-06, PT262, RKI-1447, and
CTT129253, show more potent ROCK inhibition and achieve
anti-tumor effects in pre-clinical models (reviewed in Wei
et al., 2016; Jansen et al., 2018). Several compounds displaying
selectivity for ROCK2 over ROCK1 have also been reported,
although the efficacy of these compounds has mostly been tested
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in models of other diseases, such as glaucoma, hypertension and
chronic kidney disease (Wei et al., 2016). To date, only one ROCK
inhibitor has progressed into clinical trials for cancer treatment.
AT13148 is an orally available multi-AGC kinase inhibitor that
was identified through a fragment-based screen and was found to
potently inhibit ROCK1 and ROCK2 (Yap et al., 2012). AT13148
was shown to have anti-tumor effects in pre-clinical models of
pancreatic (Rath et al., 2018), breast, prostate and uterine cancer
(Yap et al., 2012) and was well tolerated in a phase I clinical
trial in patients with advanced solid tumors (NCT01585701)
(Kumar et al., 2014).
It is important to note that pan-ROCK inhibition using
Y-27632 has been shown to increase the proliferation and
migration of a number of in vitro and in vivo cancer models
(Adachi et al., 2011; Vishnubhotla et al., 2012; Yang and Kim,
2014; Chang et al., 2018). These effects may be explained
by the observation that ROCK activation can contribute to
negative feedback mechanisms that regulate pro-proliferative
pathways. In a model of pancreatic cancer, EGF stimulation led
to increased ROCK activation, which then negatively regulated
EGFR signaling by affecting receptor trafficking. Treatment
with Y-27632 removed this negative regulation and resulted
in significantly increased AKT and MAPK signaling following
EGF stimulation (Nakashima et al., 2011). Targeting ROCK
may therefore only be appropriate in certain contexts and
combination treatments may be required to avoid compensatory
upregulation of other kinases involved in actomyosin function,
such as LIMKs and MRCKs (Rath and Olson, 2012).
MYOTONIC DYSTROPHY
KINASE-RELATED CDC42-BINDING
KINASES (MRCKS)
In humans, myotonic dystrophy kinase-related Cdc42-binding
kinases (MRCKs) form a family of three serine/threonine protein
kinases that are evolutionarily related to ROCKs and play a
key role in the regulation of actomyosin contractility (Zhao and
Manser, 2015; Leroux et al., 2018). MRCKα and MRCKβ are
ubiquitously expressed and share 85% kinase domain homology,
whilst MRCKγ is more divergent and shows a more restricted
tissue expression pattern (Unbekandt and Olson, 2014). All
MRCK proteins have an N-terminal protein kinase domain
followed by a C-terminal protein kinase C conserved region
(C1), PH-like domain, citron homology (CH) domain and CRIB
domain (Figure 3). Membrane localization of MRCKs may be
mediated at least in part by the C1 domain, which has been
shown to bind phorbol esters (Choi et al., 2008; Talman et al.,
2014), and the PH-like domain, which may bind membrane
lipids. The CH domain may facilitate substrate docking or engage
in protein-protein interactions that specify protein localization
(Unbekandt and Olson, 2014). The CRIB domains of MRCKα
and MRCKβ bind GTP-loaded Cdc42 (Leung et al., 1998) and
Rac1 (Ng et al., 2004; Schwarz et al., 2012), whilst the CRIB
domain of MRCKγ has been shown to bind to RhoQ with
higher affinity than Cdc42 and Rac1 (Ng et al., 2004). Although
the molecular mechanisms underlying MRCK activation are not
fully understood, Cdc42/Rac1 binding, membrane localization
and the release of auto-inhibitory interactions appear to be
required for MRCK signaling (Leung et al., 1998; Unbekandt and
Olson, 2014; Zhao and Manser, 2015). Recent identification of
an autophosphorylation site in MRCKα at Ser1003 led to the
development of a phospho-site specific MRCKα antibody that
can be used to assess levels of MRCKα activation and will likely
prove useful for the further elucidation of MRCKα activation
mechanisms (Unbekandt et al., 2018). Autophosphorylation of
MRCKβ at Thr1108 can be used as a readout of MRCKβ kinase
activity, although attempts to develop a suitable antibody tool
have so far been unsuccessful (Unbekandt et al., 2019).
The catalytic domains of MRCK and ROCK are highly related
and have several common substrates (Zhao and Manser, 2015).
MRCKα is known to phosphorylate LIMK1/2 (Sumi et al., 2001),
leading to phosphorylation and inhibition of cofilin (Ohashi
et al., 2000), and also promotes MLC phosphorylation through
the inhibition of MLC phosphatase (Tan et al., 2001; Wilkinson
et al., 2005) and phosphorylation of MLC on Ser19 (Leung et al.,
1998; Figure 5). However, ROCK and MRCK are not functionally
redundant and the differential regulation of ROCK and MRCK
activity plays an important role in establishing cell polarity
(Figure 6). Epithelial polarization requires the segregation of
PAR proteins into distinct cortical domains, which is driven at
least in part by an intracellular actomyosin activity gradient.
Apical actomyosin contractility is stimulated by Cdc42-MRCK
activity, whilst RhoA-ROCK activity regulates contractility along
cell-cell junctions. Apical Cdc42 activity leads to stimulation
of a Par6-aPKC complex, which in turn inhibits junctional
RhoA-ROCK signaling, establishing an actomyosin contractility
gradient (Etienne-Manneville and Hall, 2001; Zihni et al., 2017).
Differential regulation of ROCK and MRCK between different
tumor cells may also be important for invasion. Studies of
squamous cell carcinoma (SCC) cells and stromal fibroblasts
in 3D co-cultures found that collective invasion required Rho-
ROCK signaling in fibroblasts and Cdc42-MRCK signaling in
SCC cells. Imaging revealed that fibroblasts always act as the
“leading cell,” whilst SCC cells migrate through the channels
in the ECM created by the fibroblast. This remodeling of the
ECM by fibroblasts was dependent on both extracellular protease
activity and the generation of contractile force by Rho-ROCK
signaling. In contrast, the SCC cells were found to rely on
Cdc42-MRCK-mediated regulation of MLC to follow leading the
fibroblasts (Gaggioli et al., 2007).
MRCKα expression is increased in a number of human
cancers (Unbekandt and Olson, 2014) and dual inhibition of
ROCK and MRCK activity has been shown to produce a greater
inhibition of cancer cell migration and invasion than blocking
ROCK alone (Wilkinson et al., 2005; Kale et al., 2014). Widely
used ROCK inhibitors such as Y-27632 and fasudil bind to
MRCKs (Heikkila et al., 2011), although these compounds also
inhibit several other kinases and are not clinically viable (Bain
et al., 2007). Whilst dual ROCK/MRCK inhibition remains
a valid therapeutic strategy, selective MRCK inhibitors may
prove beneficial in overcoming the dose-limiting hypotension
associated with long-term ROCK inhibitor treatment (Kale et al.,
2015). The recently identified azaindole compounds BDP8900
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FIGURE 6 | Roles of ROCK, MRCK, and aPKC in the maintenance of epithelial cell polarity. Apical MRCK activation by Cdc42 leading to a local increase in
actomyosin contractility, via phosphorylation of myosin light chain (MLC) and inhibition of myosin light chain phosphatase (MLCP). Cdc42 stimulates a Par-aPKC
complex, which inhibits junctional Rho-ROCK signaling and establishes an intracellular actomyosin contractility gradient, leading to the segregation of Par proteins
into distinct cellular domains. Apical GTP-bound Cdc42 binds to Par6, which in turn binds aPKC and Par3. Activation of aPKC leads to the phosphorylation of key
polarity proteins that maintain apical-basal cell polarity.
and BDP9066 shown to have high selectivity for MRCKα and
MRCKβ over ROCK1 and ROCK2 in in vitro kinase assays and
were found to inhibit MRCK-mediated MLC phosphorylation
more potently than ROCK-mediated MLC phosphorylation in a
breast cancer cell line. MRCKα and MRCKβ are overexpressed
in squamous cell carcinoma (SCC) (Nindl et al., 2006) and
treatment of SCC cell lines with BDP9066 led to morphological
changes and decreased bundling of filamentous actin, as well as
reduced cell motility and invasion. In a mouse model of SCC,
topical application of BDP9066 reduced MRCKα activation in
the skin and resulted in a decrease in tumor volume relative
to controls. In a screen of 757 human cancer cell lines from
40 different cancer types, BDP8900 and BDP9066 treatment
produced consistent anti-proliferative effects, suggesting MRCK
may be a valid therapeutic target in a number of cancers
other than SCC (Unbekandt et al., 2018). It is important
to note that the toxicity of systemic BDP8900 and BDP9066
administration has not been studied and information regarding
the bioavailability of these compounds is not yet available.
The development of these novel MRCK-selective inhibitors
will nevertheless prove valuable for the further pre-clinical
validation of MRCK as a therapeutic target and may inform
the future development of MRCK inhibitors better suited
for clinical use.
ATYPICAL PROTEIN KINASE CS (APKCS)
The protein kinase C (PKC) family comprises three subfamilies
of serine/threonine kinases; classic PKCs (cPKCs; PKCα, PKCβ,
and PKCγ), novel PKCs (nPKC; PKCδ, PKCε, PKCη, and
PKCθ) and atypical PKCs (aPKC; PKCξ and PKCι). All PKC
proteins exist in a basally auto-inhibited conformation, which is
mediated by an interaction between the conserved C-terminal
kinase domain and an N-terminal regulatory region, which
comprises a pseudosubstrate motif and other structural domains
that vary between PKC subfamilies (Figure 3). Classic PKCs
require diacylglycerol (DAG), phosphatidylserine (PS) and Ca2+
for activation, whilst nPKCs require only interaction with DAG
and PS (Isakov, 2018). In contrast, aPKCs are primarily activated
by protein-protein interactions mediated by an N-terminal Phox
Bem1 (PB1) domain and can also be regulated by PIP3 as
well as by specific phosphorylation events (Garg et al., 2014).
Through forming a complex with Par6 and Par3, aPKCs play a
key role in establishing both the apical-basal polarity of epithelial
tissues and the front-to-rear polarity required for cell migration
downstream of Cdc42.
Most human cancers arise from epithelial tissues and the
disruption of apical-basal epithelial polarity is considered an
early event in tumorigenesis (Fomicheva et al., 2019). During
the establishment of epithelial cell polarity, GTP-bound Cdc42
binds to Par6 via its semi-CRIB domain, which in turn binds
to PKCι via a PB1-PB1 interaction (Hirano et al., 2005). The
interaction of Cdc42 with Par6-PKCι results in allosteric PKCι
activation and recruitment of Par3, which binds to PKCι and
Par6 via its PDZ domain. Par3 then targets the complex to the
apical compartment of the cell membrane through its interaction
with several cell adhesion molecules (Figure 6). Apical aPKC
activity then maintains apical-basal polarity through the
phosphorylation of a number of polarity proteins, including
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MARCKS, LGN, Lgl, GSK3β, Par1, Crumbs, and Lin5/NuMA
(Chen and Zhang, 2013). One mechanism by which human
tumors lose polarity is through loss of Par3, which leads
to mislocalization of PKCι in the cytoplasm and nucleus.
Mislocalized PKCι can remain associated with Par6 and has
been shown to contribute to maintenance of the transformed
phenotype (reviewed in Parker et al., 2014).
The Par6-aPKC complex also plays a crucial role in
establishing the front-back polarity required for directional cell
migration and invasion. PKCζ has been shown to promote
invasion and metastasis of breast cancer xenografts in mice by
promoting the nuclear localization of NFκB-p65 and suppressing
the expression of junctional proteins E-cadherin and ZO1 (Paul
et al., 2015). PKCι has also been shown to stimulate cell migration
by regulating the trafficking of protease-containing vesicles to
the plasma membrane of invadopodia. In invasive breast cancer
cell lines, the secretion of type 1-matrix metalloproteinase (MT1-
MMP) was shown to be dependent on the interaction of cortactin
and dynamin-2 on MT1-MMP containing endosomes. This
interaction was found to be regulated by the PKCι-mediated
phosphorylation of cortactin on Ser261 and depletion of PKCι
led to a decrease in the release of MT1-MMP from invadopodia
and a reduction in the degradative capacity of the cells
(Rosse et al., 2014).
In non-small cell lung cancer (NSCLC), PKCι has been shown
to promote cell survival and invasion through its action on
the Rho GEF Ect2. Binding of Ect2 to the Par6-PKCι leads
to phosphorylation of Ect2 on T328, which enhances its GEF
activity toward Rac1 (Justilien et al., 2011). PKCι-mediated Rac1
activation can stimulate MEK-ERK signaling in pancreatic cancer
cell lines, leading to increased anchorage-independent growth
in vitro and promoting tumor growth and metastasis in an
orthotopic mouse model (Scotti et al., 2010).
Overexpression of PKCι has been observed in several human
cancers, including gastric (Hashimoto et al., 2019), pancreatic
(Scotti et al., 2010), breast (Rosse et al., 2014), ovarian (Tsang
et al., 2017), prostate (Apostolatos et al., 2018), and lung
cancer (Kim et al., 2019) and has been shown to act as an
oncogenic driver in numerous studies (reviewed in Parker
et al., 2014). The role of PKCξ in cancer is less clear, with
both increased and decreased expression reported in human
tumors (Garg et al., 2014). Targeting aPKCs in cancer may
therefore only be appropriate in certain contexts. Several ATP-
competitive inhibitors have been described that show selectivity
for PKCξ /PKCι over cPKC and nPKC isoforms. For example,
CRT0066854 potently inhibits PKCι and PKCξ , with some
off-target inhibition of ROCK2 and PRK2, and was shown
to inhibit anchorage-independent cell growth and migration
in vitro (Kjaer et al., 2013). More recently, the selective aPKC
inhibitors 2-acetyl-1,3-cyclopentanedione (ACPD) and 3,4-
diaminonaphthalene-2,7-disulfonic acid (DNDA) were found
to suppress the proliferation of melanoma cell lines showing
high levels of PKCι and PKCξ expression, whilst having little
effect on the proliferation of normal melanocytes (Ratnayake
et al., 2017). Compounds that block protein-protein interactions
at the PB1 domain may provide greater selectivity for aPKCs
over other protein kinases. The gold compound aurothiomalate
(ATM) selectively inhibits the binding of Par6 to PKCι and PKCξ
(Erdogan et al., 2006; Stallings-Mann et al., 2006; Butler et al.,
2015) and has been shown to inhibit tumor growth in animal
models (Butler et al., 2015; Tsang et al., 2017). ATM is approved
for the treatment of rheumatoid arthritis (RA) and a phase I
study found ATM to be well tolerated in patients with advanced
NSCLC, ovarian cancer and pancreatic cancer (Mansfield et al.,
2013). Another gold compound used to treat RA, auranofin
(ANF), is reported to block the interaction of PKCι with Par6
more potently than ATM (Parker et al., 2014) and phase I/II trials
are ongoing to investigate the effect of ANF in combination with
an mTOR inhibitor in lung cancer (NCT01737502).
CONCLUDING REMARKS
The role of Rho GTPases as key regulators of cell migration and
invasion has been recognized for decades, yet few compounds
targeting Rho GTPase signaling networks have been developed
beyond an early preclinical stage. Due to the challenges of
inhibiting Rho GTPase activation directly, targeting Rho GTPase
effectors remains the most promising approach. Whilst PAK
and ROCK inhibitors have progressed to phase I clinical trials,
further work is needed to elucidate the context-dependent roles
of Rho GTPase effectors and to identify compensatory feedback
networks which may limit the success of these targeted therapies.
Genome sequencing of human tumors has identified several
mutations in Rho GTPases, yet the functional and clinical
significance of many of these mutants remain poorly understood.
The generation of mouse models with tissue-specific Rho GTPase
alterations will be crucial in understanding the role of these
mutants in cancer and may lead to the identification of novel
therapeutic targets within Rho GTPase signaling networks.
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